Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/6251
Title: Deprivation of arginine by recombinant human arginase in prostate cancer cells
Authors: Hsueh, EC
Knebel, SM
Lo, WHT 
Leung, TYC 
Cheng, PNM
Hsueh, CT
Keywords: Arginase
Argininosuccinate synthetase
Autophagy
Mammalian target of rapamycin
Ornithine carbamoyl transferase
Prostate cancer
Issue Date: 30-Apr-2012
Publisher: BioMed Central Ltd.
Source: Journal of hematology & oncology, 30 Apr. 2012, v. 5, 17, p. 1-6 How to cite?
Journal: Journal of hematology & oncology 
Abstract: Background: Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer, and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-proliferative activity in cancer cells deficient in the expression of ornithine carbamoyl transferase (OCT). Interestingly, a variety of cancer cells such as melanoma and prostate cancer deficient in argininosuccinate synthetase (ASS) are sensitive to arginine deprivation by arginine deiminase. In this study, we investigated levels of gene expression of OCT and ASS, and the effects of rhArg in human prostate cancer cells: LNCaP (androgen-dependent), PC-3 and DU-145 (both androgen-independent).
Results: Quantitative real-time PCR showed minimal to absent gene expression of OCT, but ample expression of ASS expression in all 3 cell lines. Cell viability assay after 72-h exposure of rhArg showed all 3 lines had half maximal inhibitory concentration less than or equal to 0.02 U/ml. Addition of ornithine to cell culture media failed to rescue these cells from rhArg-mediated cytotoxicity. Decreased phosphorylation of 4E-BP1, a downstream effector of mammalian target of rapamycin (mTOR), was noted in DU-145 and PC-3 after exposure to rhArg. Moreover, there was no significant apoptosis induction after arginine deprivation by rhArg in all 3 prostate cancer cell lines.
Conclusion: rhArg causes significant cytotoxicity in LNCaP, DU-145 and PC-3 prostate cancer cells which all demonstrate decreased OCT expression. Inhibition of mTOR manifested by hypophosphorylation of 4E-BP1 suggests autophagy is involved as alternative cell death mechanism. rhArg demonstrates a promising novel agent for prostate cancer treatment.
URI: http://hdl.handle.net/10397/6251
ISSN: 1756-8722
DOI: 10.1186/1756-8722-5-17
Rights: © 2012 Hsueh et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Hsueh_Arginine_Recombinant_Cancer.pdf516.75 kBAdobe PDFView/Open
SFX Query Show full item record

SCOPUSTM   
Citations

29
Last Week
0
Last month
0
Citations as of Dec 17, 2017

WEB OF SCIENCETM
Citations

28
Last Week
0
Last month
0
Citations as of Dec 17, 2017

Page view(s)

170
Last Week
1
Last month
Citations as of Dec 10, 2017

Download(s)

79
Citations as of Dec 10, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.